Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Short-term Investments (2016 - 2017)

Historic Short-term Investments for Northwest Biotherapeutics (NWBO) over the last 4 years, with Q1 2017 value amounting to $397000.0.

  • Northwest Biotherapeutics' Short-term Investments fell 4678.28% to $397000.0 in Q1 2017 from the same period last year, while for Mar 2017 it was $397000.0, marking a year-over-year decrease of 4678.28%. This contributed to the annual value of $685000.0 for FY2016, which is 2268.62% down from last year.
  • According to the latest figures from Q1 2017, Northwest Biotherapeutics' Short-term Investments is $397000.0, which was down 4678.28% from $685000.0 recorded in Q4 2016.
  • Northwest Biotherapeutics' Short-term Investments' 5-year high stood at $1.0 million during Q2 2015, with a 5-year trough of $397000.0 in Q1 2017.
  • For the 4-year period, Northwest Biotherapeutics' Short-term Investments averaged around $779400.0, with its median value being $806000.0 (2014).
  • As far as peak fluctuations go, Northwest Biotherapeutics' Short-term Investments surged by 242.77% in 2015, and later crashed by 4678.28% in 2017.
  • Northwest Biotherapeutics' Short-term Investments (Quarter) stood at $865000.0 in 2014, then grew by 2.43% to $886000.0 in 2015, then dropped by 22.69% to $685000.0 in 2016, then tumbled by 42.04% to $397000.0 in 2017.
  • Its Short-term Investments was $397000.0 in Q1 2017, compared to $685000.0 in Q4 2016 and $685000.0 in Q3 2016.